Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acutus Medical, Inc.AFIB · Entity 83848 | Director | June 15, 2023 | June 15, 2023 |
| Envista Holdings CorpNVST · Entity 4007 | Director | May 19, 2026 | May 21, 2026 |
| Hyperfine, Inc.HYPR · Entity 6865 | Director | June 12, 2024 | June 12, 2024 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 05, 2026 | June 05, 2026 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
| REVA Medical, Inc.RVA:AX · Entity 11998 | Director | July 09, 2017 | July 11, 2017 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | June 15, 2020 | June 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acutus Medical, Inc.
Report date June 15, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| FORM 4SEC Table I · non-derivative | Direct | 21,840 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 10,920 · Balance 21,840 F1: Common Stock F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. |
| FORM 4SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-15 | Direct | 25,480 |
Reported balance
After 2023-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-15 · Grant · Acquired 25,480 · Balance 25,480 F4: Stock Options (Right to Buy) F5: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1: Common Stock |
| FORM 4SEC Table I · non-derivative | IndirectBy Front Foot Trust | 507,509 |
Reported balance
Holding disclosure · report date 2023-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 507,509 F1: Common Stock F3: The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock
F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.
F3: The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F4: Stock Options (Right to Buy)
F5: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director.
Envista Holdings Corp
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,105 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 12,585 · Balance 82,105 F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.
Hyperfine, Inc.
Report date June 12, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2034-06-12 | Direct | 79,200 |
Reported balance
After 2024-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 79,200 · Balance 79,200 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date.
NeuroPace Inc
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,890 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 2,890 · Balance 2,890 F1: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.74 · Expires 2036-06-04 | Direct | 5,368 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 5,368 · Balance 5,368 F2: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
F2: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
REVA Medical, Inc.
Report date July 09, 2017 · Filed July 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,300 |
Reported balance
After 2017-07-09 transaction · row 1
1 source rowRow 1 · 2017-07-09 · Grant · Acquired 6,000 · Balance 27,300 F1: These restricted stock units will vest in full on the earlier of (i) July 9, 2018 or (ii) the day prior to the Issuer's 2018 annual stockholder meeting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2027-07-09 | Direct | 10,500 |
Reported balance
After 2017-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-09 · Grant · Acquired 10,500 · Balance 10,500 F2: The option shares shall vest in four equal quarterly installments, with the first installment on October 9, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in full on the earlier of (i) July 9, 2018 or (ii) the day prior to the Issuer's 2018 annual stockholder meeting.
F2: The option shares shall vest in four equal quarterly installments, with the first installment on October 9, 2017.
ViewRay, Inc.
Report date June 15, 2020 · Filed June 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,670 |
Reported balance
After 2020-06-15 transaction · row 1
1 source rowRow 1 · 2020-06-15 · Grant · Acquired 52,752 · Balance 99,670 F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EndoChoice Holdings, Inc.
Report date November 22, 2016 · Filed November 23, 2016
Section 16 reporting ended · disclosed 2016-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Saol Capital LLC | 0 |
Reported balance
After 2016-11-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-11-22 · Disposition to issuer · Disposed 26,666 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F2: Saol Capital LLC is owned equally by The Huennekens Family Trust dated June 14, 2007 and The Kieran and Mary Ellen Gallahue Revocable Family Trust dated January 24, 2004, as amended, which hold voting and dispositive power with respect thereto. The Huennekens Family Trust dated June 14, 2007 is owned directly and equally by the reporting person and Deborah Legome Huennekens. The Kieran and Mary Ellen Gallahue Revocable Trust is owned directly and equally by Kieran Thomas Gallahue and Mary Ellen Gallahue. By virtue of the relationships described in this footnote, the entities and individuals described herein may be deemed to beneficially own the shares owned by Saol Capital. |
| Common stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Front Foot Trust | 0 |
Reported balance
After 2016-11-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-11-22 · Disposition to issuer · Disposed 8,423 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F3: Shares previously directly held by the reporting person were transferred to Front Foot Trust on September 1, 2016. Front Foot Trust is owned directly and equally by the reporting person and Deborah Legome Huennekens and may therefore be deemed to beneficially own the shares owned by Front Foot Trust. |
| Common stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-22 transaction · row 3
1 source rowRow 3 · 2016-11-22 · Disposition to issuer · Disposed 47,446 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
F2: Saol Capital LLC is owned equally by The Huennekens Family Trust dated June 14, 2007 and The Kieran and Mary Ellen Gallahue Revocable Family Trust dated January 24, 2004, as amended, which hold voting and dispositive power with respect thereto. The Huennekens Family Trust dated June 14, 2007 is owned directly and equally by the reporting person and Deborah Legome Huennekens. The Kieran and Mary Ellen Gallahue Revocable Trust is owned directly and equally by Kieran Thomas Gallahue and Mary Ellen Gallahue. By virtue of the relationships described in this footnote, the entities and individuals described herein may be deemed to beneficially own the shares owned by Saol Capital.
F3: Shares previously directly held by the reporting person were transferred to Front Foot Trust on September 1, 2016. Front Foot Trust is owned directly and equally by the reporting person and Deborah Legome Huennekens and may therefore be deemed to beneficially own the shares owned by Front Foot Trust.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 1,360 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2021 Filed Jan 11, 2022 02:41 UTC Amendment | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 237,437 | Not disclosed Strike: $3.27 | Not disclosed |
DisclosureSEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F7 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share. F5 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") F6 · derivative.exercise_date: within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within three years of the closing of the IPO; or (3) the closing of a private financing round within three years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 1.5 times $3.92 (as adjusted). Read SEC document |
| December 22, 2021 Filed Jan 11, 2022 02:41 UTC Amendment | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 712,312 | Not disclosed Strike: $3.27 | Not disclosed |
DisclosureSEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,312 Underlying: Class A Common Stock · 712,312 shares Expires 2031-04-27 F3 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), F4 · price: pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 2,175,000 shares of Hyperfine common stock for $1.07 per share. F2 · derivative.exercise_date: The shares underlying this option vest as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following 36 months, subject to Mr. Huennekens' continued service on each vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:51 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 5,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-21-000082 · wf-form4_162214865673410.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,425 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the date of the Issuer's 2022 Annual Meeting of Stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. RSUs are payable in shares of common stock on a one-to-one basis. F2 · balance_after: Includes 21,970 RSUs that were previously reported in Table II. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034547 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:08 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 52,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037383 · doc4.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,670 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| May 28, 2020 Filed May 29, 2020 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 3,095 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033001 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,095 Underlying: Common Stock · 3,095 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:24 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantRestricted Stock Unit · Derivative | 11,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001375 · form4-05292020_010519.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,170 Underlying: Common Stock · 11,170 shares Expires 2030-05-26 F1 · derivative.exercise_price: Restricted stock units are payable in shares of common stock on a one-to-one basis. F2 · derivative.exercise_date: The restricted stock units granted will vest on the date of the Issuer's 2021 annual meeting of stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the issuer. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:08 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 12,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002088 · doc4.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,918 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 12, 2020, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| May 09, 2019 Filed May 10, 2019 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029058 · doc4.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 Underlying: Common Stock · 2,577 shares Expires not disclosed F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F4 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| May 09, 2019 Filed May 10, 2019 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029058 · doc4.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on October 1, 2018 and is fully vested. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on October 1, 2018 and is fully vested. Read SEC document |
| May 09, 2019 Filed May 10, 2019 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029058 · doc4.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Company equity awards as disclosed on this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:18 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 18,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-19-000199 · ownership.xml · nonDerivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,211 F3 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:18 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 9,740 | $6.16 | $59,998.40 |
DisclosureSEC source: 0000950103-19-000199 · ownership.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,543 F1 · shares: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $60,000. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 02:46 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 32,547 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000950103-18-015065 · dp100063_4-huennekens.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,547 Underlying: Common Stock · 32,547 shares Expires 2028-12-21 F1 · derivative.exercise_date: All of the shares subject to the option had vested and were exercisable as of December 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 1,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054044 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360 Underlying: Common Stock · 1,360 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the date of the Issuer's 2019 Annual Meeting of Stockholders. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:01 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 1,941 | $8.18 | $15,877.38 |
DisclosureSEC source: 0000950103-18-009417 · dp94313_4-huennekens.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,803 F1 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $15,879. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:44 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 3,862 | $7.12 | $27,497.44 |
DisclosureSEC source: 0000950103-18-008368 · dp93191_4-huennekens.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,862 F1 · shares: 1/6th of these shares shall vest and become exercisable on the last day of each calendar month beginning on July 31, 2018, such that 100% of the shares will be vested on December 31, 2018, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $27,500. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 02:37 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 38,622 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000950103-18-003005 · dp87796_4-huennekens.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,622 Underlying: Common Stock · 38,622 shares Expires 2028-03-01 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest and become exercisable on each monthly anniversary measured from March 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person remaining a service provider through each such vesting date. Read SEC document |
| July 09, 2017 Filed Jul 11, 2017 20:15 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantStock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-17-044827 · doc4.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-07-09 F2 · derivative.exercise_date: The option shares shall vest in four equal quarterly installments, with the first installment on October 9, 2017. Read SEC document |
| July 09, 2017 Filed Jul 11, 2017 20:15 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044827 · doc4.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 F1 · shares: These restricted stock units will vest in full on the earlier of (i) July 9, 2018 or (ii) the day prior to the Issuer's 2018 annual stockholder meeting. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 15:22 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerCommon stock, par value $0.001 per share | 47,446 | $8.00 | $379,568.00 |
DisclosureSEC source: 0001623919-16-000100 · wf-form4_147991453354204.xml · nonDerivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 15:22 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerCommon stock, par value $0.001 per share | 8,423 | $8.00 | $67,384.00 |
DisclosureSEC source: 0001623919-16-000100 · wf-form4_147991453354204.xml · nonDerivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Front Foot Trust Disclosed balance after: 0 F1 · acquired: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F3 · ownership.nature: Shares previously directly held by the reporting person were transferred to Front Foot Trust on September 1, 2016. Front Foot Trust is owned directly and equally by the reporting person and Deborah Legome Huennekens and may therefore be deemed to beneficially own the shares owned by Front Foot Trust. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 15:22 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerCommon stock, par value $0.001 per share | 26,666 | $8.00 | $213,328.00 |
DisclosureSEC source: 0001623919-16-000100 · wf-form4_147991453354204.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Saol Capital LLC Disclosed balance after: 0 F1 · acquired: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F2 · ownership.nature: Saol Capital LLC is owned equally by The Huennekens Family Trust dated June 14, 2007 and The Kieran and Mary Ellen Gallahue Revocable Family Trust dated January 24, 2004, as amended, which hold voting and dispositive power with respect thereto. The Huennekens Family Trust dated June 14, 2007 is owned directly and equally by the reporting person and Deborah Legome Huennekens. The Kieran and Mary Ellen Gallahue Revocable Trust is owned directly and equally by Kieran Thomas Gallahue and Mary Ellen Gallahue. By virtue of the relationships described in this footnote, the entities and individuals described herein may be deemed to beneficially own the shares owned by Saol Capital. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.